Luxa Biotechnology Appoints Dr. Keith Dionne as CEO to Lead Advanced RPESC Therapy Development
Slice of Healthcare Team
Oct 04, 2024
Key Highlights
- Dr. Keith Dionne appointed as CEO of Luxa Biotechnology.
- Luxa develops a novel RPESC therapy for dry AMD and Geographic Atrophy (GA).
- Dionne brings 30 years of experience, including strategic biotech leadership roles.
- Luxa aims to address the unmet need for vision restoration in dry AMD/GA patients.
Source: Business Wire
Notable Quotes
“ We are excited to welcome Keith to the Luxa team. He is the ideal leader to help advance our mission to restore vision for patients with dry AMD/GA. ”
Dr. Sally Temple, Chief Scientific Officer at Luxa
“ I am honored to join Luxa at such an exciting time. The company’s innovative RPESC therapy represents an important breakthrough. ”
Dr. Keith Dionne, CEO at Luxa Biotechnology
